Inhibition of tumor growth and angiogenesis of tamoxifen‑resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor

Ji Eun Kim(Dongguk University), Keon Wook Kang(Cancer Research Institute)
Oncology Letters
February 20, 2019
Cited by 61


Related Papers